BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This study was design to:
* To assess the impact of a biweekly (experimental arm) compared to a conventional administration (control arm) on the rate of grade 3-4 neutropenia in metastatic colorectal cancer (mCRC) patients treated with trifluridine/tipiracil plus bevacizumab, and
* To identify predictive clinical and biological factors for grade 3-4 neutropenia in this patient population.
Phase:
PHASE2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborator:
Servier
Treatments:
Bevacizumab trifluridine tipiracil drug combination